Interferon-λ treatment accelerates sars-cov-2 clearance despite age-related delays in the induction of t cell immunity

HIGHLIGHTS

• who: Deanna M. Santer from the Subjects were recruited for a randomised, double-blind, placebocontrolled study from outpatient testing centers at six institutions in Toronto, CanadaEligible individuals had a SARS-Co, infection confirmed by nasopharyngeal swab and were enrolled within , days of symptom onset or first positive test if asymptomatic. The health research ethics boards of all participating institutions approved this study (University of Toronto, University of Alberta, University of Manitoba) using samples collected from the approved trial, which was registered (NCT04354259) and done under a Clinical Trial Application approved by Health Canada. All participants provided written . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.